Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.

Cancer biology & therapy - 2 Nov 2017

Zhao Hongjuan, Nolley Rosalie, Chan Andy M W, Rankin Erinn B, Peehl Donna M

Abstract excerpt

MET plays an important role in the development and progression of papillary renal cell carcinoma (pRCC). Evaluation of efficacy of MET inhibitors against pRCC has been hampered by limited preclinical models depicting MET abnormalities. We established a new patient-derived xenograft (PDX) model of pRCC carrying an activating mutation of MET and tested the ability of cabozantinib, an inhibitor of receptor tyrosine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to Kidney Neoplasms

Share to Neoplasm Metastasis

Share to Pyridines

Share to Receptor Protein-Tyrosine Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 27715452
DOI: 10.1080/15384047.2016.1219816
PMCID: PMC5710673

Genes

MET
RAG2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.PMID 27715452Read ↗

Papillary renal cell carcinoma: A review of the current therapeutic landscape.Semantic proximity Read ↗

Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.Semantic proximity Read ↗

CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.Semantic proximity Read ↗

Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.Semantic proximity Read ↗

Papillary renal cell carcinoma: current progress and future directions.Semantic proximity Read ↗

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.Semantic proximity Read ↗

Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patientsSemantic proximity Read ↗

Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma.Semantic proximity Read ↗

Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.Semantic proximity Read ↗

Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell CarcinomaSemantic proximity Read ↗

Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Semantic proximity Read ↗

Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.